You thought wrong
The company itself has asserted -
“Composition of matter” and “method of treatment” US patents have been granted for RYONCIL and other mesenchymal precursor / stromal cell products to treat GVHD through to 2032.
I merely posted links to a few GvHD patents, there are numerous.
Not sure why there is a beat up on otherperspective when it is a company statement. Perhaps a few feathers have been ruffled over Op's query re Cynata's use of cryopreservation- how about you check that and we can have a conversation
Reg
You thought wrongThe company itself has asserted - “Composition...
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |